Buscar
Nuvalent Inc
NUVLAñadir a la lista de seguimiento
123.965USD
0.0000.00%
Cierre 07-14 16:00（ET）Cotizaciones retrasadas 15 min
9.81BCap. mercado
PérdidaP/E TTM
Más Datos de Nuvalent Inc Compañía
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. It develops small molecules that have the potential to overcome resistance, minimize adverse events, and address brain metastases. It is advancing a robust pipeline with investigational candidates for ROS proto-oncogene 1 (ROS1)-positive, anaplastic lymphoma kinase (ALK)-positive, and human epidermal growth factor receptor 2 (HER2)-positive non-small cell lung cancer, and multiple discovery-stage research programs. Its product candidate, Zidesamtinib (NVL-520), is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel ROS1-selective inhibitor. Its product candidate, Neladalkib (NVL-655), is being developed for patients with ALK-positive NSCLC. NVL-655 is a brain-penetrant ALK-selective inhibitor. Its product candidate, NVL-330, is a brain-penetrant HER2-selective inhibitor.
Información de Nuvalent Inc
Símbolo de cotizaciónNUVL
Nombre de la empresaNuvalent Inc
Fecha de salida a bolsaJul 29, 2021
Director ejecutivoPorter (James R)
Número de empleados142
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 29
DirecciónOne Broadway, 14Th Floor
CiudadCAMBRIDGE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02142
Teléfono18573577000
Sitio Webhttps://www.nuvalent.com/
Símbolo de cotizaciónNUVL
Fecha de salida a bolsaJul 29, 2021
Director ejecutivoPorter (James R)
Ejecutivos de Nuvalent Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Matthew Shair, Ph.D.
Dr. Matthew Shair, Ph.D.
Director, Scientific Founder, Head Scientific Advisor
Director, Scientific Founder, Head Scientific Advisor
1.59M
-0.37%
Dr. Henry E. Pelish, Ph.D.
Dr. Henry E. Pelish, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
63.49K
-3.32%
Ms. Alexandra (Alex) Balcom, CPA
Ms. Alexandra (Alex) Balcom, CPA
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
44.43K
--
Ms. Darlene Noci
Ms. Darlene Noci
Chief Development Officer
Chief Development Officer
17.02K
--
Dr. Sapna Srivastava, Ph.D.
Dr. Sapna Srivastava, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
5.94K
+57.95%
Dr. Michael L. Meyers, M.D., Ph.D.
Dr. Michael L. Meyers, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
5.94K
+57.95%
Dr. Joseph Pearlberg, M.D., Ph.D.
Dr. Joseph Pearlberg, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
5.15K
+51.44%
Ms. Christy J. Oliger
Ms. Christy J. Oliger
Independent Director
Independent Director
3.44K
--
Dr. James R. (Jim) Porter, Ph.D.
Dr. James R. (Jim) Porter, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Christopher D. Turner, M.D.
Dr. Christopher D. Turner, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Matthew Shair, Ph.D.
Dr. Matthew Shair, Ph.D.
Director, Scientific Founder, Head Scientific Advisor
Director, Scientific Founder, Head Scientific Advisor
1.59M
-0.37%
Dr. Henry E. Pelish, Ph.D.
Dr. Henry E. Pelish, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
63.49K
-3.32%
Ms. Alexandra (Alex) Balcom, CPA
Ms. Alexandra (Alex) Balcom, CPA
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
44.43K
--
Ms. Darlene Noci
Ms. Darlene Noci
Chief Development Officer
Chief Development Officer
17.02K
--
Dr. Sapna Srivastava, Ph.D.
Dr. Sapna Srivastava, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
5.94K
+57.95%
Dr. Michael L. Meyers, M.D., Ph.D.
Dr. Michael L. Meyers, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
5.94K
+57.95%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Nuvalent Inc?
Los cinco principales accionistas de Nuvalent Inc son: Dr. Matthew Shair, Ph.D.
¿Cuántas instituciones poseen acciones de Nuvalent Inc (NUVL)?
A fecha de 2026Q1, 490 instituciones poseen acciones de Nuvalent Inc, con un valor de mercado combinado de aproximadamente 86.91M, lo que representa el 118.14% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 5876768.00.